This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsSilo Wellness (SILF.F) 주식 개요A psychedelics and wellness company, develops psychedelic medicine to reduce trauma. 자세히 보기SILF.F 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적2/6재무 건전성0/6배당0/6강점주가수익률(2.2x)이 US 시장(18.6x)보다 낮습니다.올해부터 흑자전환위험 분석의미 있는 시가총액이 없습니다($1M)수익이 USD$1m 미만입니다($276K)마이너스 주주 지분지난 1년 동안 주주가 크게 희석되었습니다.+ 위험 3건 추가모든 위험 점검 보기SILF.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.011202.7% 고평가 내재 할인율Est. Revenue$PastFuture-5m511k2016201920222025202620282031Revenue US$275.9kEarnings US$511.0kAdvancedSet Fair ValueView all narrativesSilo Wellness Inc. 경쟁사Evofem BiosciencesSymbol: OTCPK:EVFMMarket cap: US$866.7kSeelos TherapeuticsSymbol: OTCPK:SEEL.QMarket cap: US$136.0Kaya HoldingsSymbol: OTCPK:KAYSMarket cap: US$23.3mWEEDSymbol: OTCPK:BUDZMarket cap: US$4.6m가격 이력 및 성과Silo Wellness 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가CA$0.01152주 최고가CA$0.02952주 최저가CA$0.0037베타0.661개월 변동0%3개월 변동53.42%1년 변동26.41%3년 변동n/a5년 변동n/aIPO 이후 변동-99.63%최근 뉴스 및 업데이트공시 • Aug 30+ 1 more updateSilo Wellness Inc. announced that it expects to receive CAD 0.25 million in fundingSilo Wellness Inc. announced a best-efforts private placement to issue 12,500,000 common shares at a price of CAD 0.02 per share for the gross proceeds of CAD 250,000 on August 29, 2023.공시 • Feb 18Silo Wellness Inc. Announces Resignation of Gerard Lee from as A Director of the BoardSilo Wellness Inc. accepted the resignation of Gerard Lee from his position as a director of the board, effective immediately. The board of directors includes Greg Biniowsky (independent director), Vancouver lawyer; Simon Bababeygy, M.D. (independent director), California physician; Michael Hartman, California pharmaceutical chemist; and Mike Arnold, Oregon lawyer.공시 • Oct 18Silo Wellness Inc. (CNSX:SILO) completed the acquisition of Dyscovry Science Ltd.Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd. on May 31, 2022. Silo Wellness Inc. (CNSX:SILO) entered into a definitive share exchange agreement to acquire Dyscovry Science Ltd. on September 27, 2022. Pursuant to the terms of the Share Exchange Agreement, Silo will acquire 100% of the issued and outstanding shares of Dyscovry in exchange for 12,762,325 (for a total of 49% of the issued shares post closing of the transaction) common shares in the capital of Silo (the "Payment Shares"). The Payment Shares issued for shares of Dyscovry shall be subject to restrictions on resale for a period of 36 months from closing of the Acquisition and shall be released on a schedule consistent with the release schedule for an "emerging issuer" prescribed by section 4.3 of National Policy 46-201- Escrow for Initial Public Offerings. Silo has also agreed to pay approximately CAD 120,000 of Dyscovry founder's debt in twelve equal monthly installments, and in any event, the total debt shall be paid no later than twelve months from the Closing Date. Subject to the completion of the due diligence process and the completion of the definitive agreement, the transaction contemplates Silo will acquire 100% of the issued and outstanding shares of Dyscovry in exchange of 49% of the issued shares. Following closing, Dyscovry shall have the right to immediately nominate one director to the board of directors of Silo. Closing of the Transaction is subject to customary closing conditions and applicable regulatory approvals, including the approval of the CSE and the shareholders of Dyscovry if required. Silo Wellness Inc. (CNSX:SILO) completed the acquisition of Dyscovry Science Ltd. on October 17, 2022. Upon closing of the transaction, CFO Winfield Ding has resigned from the board of directors and Dyscovry founder Gerard Lee of Toronto has been appointed director. Winfield Ding will continue as Chief Financial Officer.공시 • Jun 10Silo Wellness Inc. Announces Change of Chief Executive OfficerSilo Wellness Inc. announced that founder and chairman of the board of directors Mike Arnold is assuming the role of the company's interim chief executive officer to continue to lead the company through its planned acquisition of Dyscovry Science Ltd. and in its planned Oregon psilocybin business objectives. The company and former CEO Douglas K. Gordon have agreed to Mr. Gordon stepping down as CEO, but he will remain involved in the business, including pursuit of global distribution opportunities for sales of Marley One. During his tenure at Silo Wellness, Mr. Gordon was responsible for the creation of the Marley One global mushroom brand in collaboration with the family of legendary musician Bob Marley and for launching psychedelic retreats in Oregon and Jamaica, a first for a publicly traded company. He also led the Company through its public listing in March of 2021 and two major financings. CEO Mike Arnold founded Silo Wellness in 2018 and was CEO from inception until August 2020. He is an experienced Oregon trial attorney. As the company's president and chairman of the board of directors, he has been responsible for the Company's Ontario Securities Commission and Canadian Securities Exchange compliance, investor relations, financing, and corporate development. In the last five years he has successfully raised over $12 million for his startups. Mike received his Bachelor of Arts from Truman State University (Kirksville, Missouri) and Juris Doctor from the University of Oregon School of Law. He is an avid outdoorsman and rafting guide.공시 • Jun 01Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd.Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd. on May 31, 2022. Subject to the completion of the due diligence process and the completion of the definitive agreement, the transaction contemplates Silo Wellness Inc. acquiring 100% of Dyscovry's shares in exchange for 49% of the issued outstanding securities of the Company.공시 • Apr 15Silo Wellness Inc. announced that it expects to receive CAD 5.95 million in funding from Alpha Blue Ocean Investment GroupSilo Wellness Inc. announced that it has entered into an subscription agreement for a private placement of convertible debentures for gross proceeds of up to CAD 5,950,000 on April 14, 2022. The transaction will include participation from new investor Global Tech Opportunities 14, a fund managed by Alpha Blue Ocean Investment Group. The subscription agreement provides a commitment to fund the corporation up to CAD 5,950,000 by subscribing for CAD 7,300,000 aggregate principal amount of convertible debentures, inclusive of the commitment fee, in twenty tranches, each in the aggregate principal amount of CAD 350,000 each tranche convertible upon notice at the lower of the closing price of the common shares on the CSE at the time of delivery of the relevant conversion notice to the corporation and CAD 0.05; the convertible debentures shall be subscribed for at a subscription price of eighty-five percent of the par value of the convertible debentures. 41,650,000 warrants exercisable at CAD 0.05 shall be attached to the first tranche. In connection with the subscription agreement, the company has agreed to pay the subscriber a commitment fee of CAD 300,000 where CAD 150,000 shall be added to the principal amount of the debentures issued in connection with each of the first two tranches.더 많은 업데이트 보기Recent updates공시 • Aug 30+ 1 more updateSilo Wellness Inc. announced that it expects to receive CAD 0.25 million in fundingSilo Wellness Inc. announced a best-efforts private placement to issue 12,500,000 common shares at a price of CAD 0.02 per share for the gross proceeds of CAD 250,000 on August 29, 2023.공시 • Feb 18Silo Wellness Inc. Announces Resignation of Gerard Lee from as A Director of the BoardSilo Wellness Inc. accepted the resignation of Gerard Lee from his position as a director of the board, effective immediately. The board of directors includes Greg Biniowsky (independent director), Vancouver lawyer; Simon Bababeygy, M.D. (independent director), California physician; Michael Hartman, California pharmaceutical chemist; and Mike Arnold, Oregon lawyer.공시 • Oct 18Silo Wellness Inc. (CNSX:SILO) completed the acquisition of Dyscovry Science Ltd.Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd. on May 31, 2022. Silo Wellness Inc. (CNSX:SILO) entered into a definitive share exchange agreement to acquire Dyscovry Science Ltd. on September 27, 2022. Pursuant to the terms of the Share Exchange Agreement, Silo will acquire 100% of the issued and outstanding shares of Dyscovry in exchange for 12,762,325 (for a total of 49% of the issued shares post closing of the transaction) common shares in the capital of Silo (the "Payment Shares"). The Payment Shares issued for shares of Dyscovry shall be subject to restrictions on resale for a period of 36 months from closing of the Acquisition and shall be released on a schedule consistent with the release schedule for an "emerging issuer" prescribed by section 4.3 of National Policy 46-201- Escrow for Initial Public Offerings. Silo has also agreed to pay approximately CAD 120,000 of Dyscovry founder's debt in twelve equal monthly installments, and in any event, the total debt shall be paid no later than twelve months from the Closing Date. Subject to the completion of the due diligence process and the completion of the definitive agreement, the transaction contemplates Silo will acquire 100% of the issued and outstanding shares of Dyscovry in exchange of 49% of the issued shares. Following closing, Dyscovry shall have the right to immediately nominate one director to the board of directors of Silo. Closing of the Transaction is subject to customary closing conditions and applicable regulatory approvals, including the approval of the CSE and the shareholders of Dyscovry if required. Silo Wellness Inc. (CNSX:SILO) completed the acquisition of Dyscovry Science Ltd. on October 17, 2022. Upon closing of the transaction, CFO Winfield Ding has resigned from the board of directors and Dyscovry founder Gerard Lee of Toronto has been appointed director. Winfield Ding will continue as Chief Financial Officer.공시 • Jun 10Silo Wellness Inc. Announces Change of Chief Executive OfficerSilo Wellness Inc. announced that founder and chairman of the board of directors Mike Arnold is assuming the role of the company's interim chief executive officer to continue to lead the company through its planned acquisition of Dyscovry Science Ltd. and in its planned Oregon psilocybin business objectives. The company and former CEO Douglas K. Gordon have agreed to Mr. Gordon stepping down as CEO, but he will remain involved in the business, including pursuit of global distribution opportunities for sales of Marley One. During his tenure at Silo Wellness, Mr. Gordon was responsible for the creation of the Marley One global mushroom brand in collaboration with the family of legendary musician Bob Marley and for launching psychedelic retreats in Oregon and Jamaica, a first for a publicly traded company. He also led the Company through its public listing in March of 2021 and two major financings. CEO Mike Arnold founded Silo Wellness in 2018 and was CEO from inception until August 2020. He is an experienced Oregon trial attorney. As the company's president and chairman of the board of directors, he has been responsible for the Company's Ontario Securities Commission and Canadian Securities Exchange compliance, investor relations, financing, and corporate development. In the last five years he has successfully raised over $12 million for his startups. Mike received his Bachelor of Arts from Truman State University (Kirksville, Missouri) and Juris Doctor from the University of Oregon School of Law. He is an avid outdoorsman and rafting guide.공시 • Jun 01Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd.Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd. on May 31, 2022. Subject to the completion of the due diligence process and the completion of the definitive agreement, the transaction contemplates Silo Wellness Inc. acquiring 100% of Dyscovry's shares in exchange for 49% of the issued outstanding securities of the Company.공시 • Apr 15Silo Wellness Inc. announced that it expects to receive CAD 5.95 million in funding from Alpha Blue Ocean Investment GroupSilo Wellness Inc. announced that it has entered into an subscription agreement for a private placement of convertible debentures for gross proceeds of up to CAD 5,950,000 on April 14, 2022. The transaction will include participation from new investor Global Tech Opportunities 14, a fund managed by Alpha Blue Ocean Investment Group. The subscription agreement provides a commitment to fund the corporation up to CAD 5,950,000 by subscribing for CAD 7,300,000 aggregate principal amount of convertible debentures, inclusive of the commitment fee, in twenty tranches, each in the aggregate principal amount of CAD 350,000 each tranche convertible upon notice at the lower of the closing price of the common shares on the CSE at the time of delivery of the relevant conversion notice to the corporation and CAD 0.05; the convertible debentures shall be subscribed for at a subscription price of eighty-five percent of the par value of the convertible debentures. 41,650,000 warrants exercisable at CAD 0.05 shall be attached to the first tranche. In connection with the subscription agreement, the company has agreed to pay the subscriber a commitment fee of CAD 300,000 where CAD 150,000 shall be added to the principal amount of the debentures issued in connection with each of the first two tranches.공시 • Feb 04Silo Wellness Inc. announced that it expects to receive $0.494988 million in funding from Orthogonal Thinker, Inc., Investment ArmSilo Wellness Inc. announced that it has entered into an subscription agreement to issue 12,555,180 units at a price of $0.039425 per unit for gross proceeds of up to $494,988 on February 3, 2022. The transaction will include participation from new investor Orthogonal Thinker, Inc., Investment Arm. Each unit will consist of one common share and one common share purchase warrant. Each warrant will be exercisable at CAD 0.05 per share for two years following the closing date of the offering. The offering is subject to customary closing conditions, applicable regulatory approvals, including receipt of certain voting support agreements from certain shareholders of the company. David Nikzad and Jason Hobson from Orthogonal Thinker, Inc., Investment Arm will join company's board of director.공시 • Jun 25Silo Wellness Inc. Debuts Marley One, the First Global Functional and Psychedelic Mushroom Brand, in Collaboration with the Bob Marley FamilySilo Wellness Inc. announced the launch of Marley One, the first global functional and psychedelic mushroom consumer brand, in collaboration with the family of Bob Marley. The initial product offering will include a range of functional mushroom tinctures with unique blends highlighting the brand’s connection to Jamaica, including species such as cordyceps, lion's mane, chaga, reishi and turkey tail that offer a range of unique health and wellness benefits, from immunity and gut health to cognitive function and sleep enhancement. The Company intends to launch a psychedelic mushroom product line under the Marley name later this year, to be followed by additional functional mushroom products including gummies, capsules and cosmetics. In March, Silo Wellness announced a multi-year licensing agreement with the family of global reggae icon Bob Marley for the exclusive worldwide rights to brand, market and sell a distinct product line of functional and psychedelic mushrooms. At launch, the Marley One product line includes: One Mind: A coffee-flavored blend of lion’s mane and L-theanine designed to improve focus and cognitive function. One Flow: A peppermint-flavored blend of cordyceps and ginseng designed to enhance physical endurance and mental function. One Harmony: A mango-flavored blend of chaga and ginger designed to stimulate gut health and improve digestion. One Body: A berry-flavored blend of turkey tail and astragalus designed to support immune health. One Rest: A vanilla-flavored blend of reishi and GABA designed to help reduce tension and stress and improve quality of sleep.주주 수익률SILF.FUS PharmaceuticalsUS 시장7D0%4.9%1.0%1Y26.4%44.2%28.7%전체 주주 수익률 보기수익률 대 산업: SILF.F은 지난 1년 동안 44.2%의 수익을 기록한 US Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: SILF.F은 지난 1년 동안 28.7%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.주가 변동성Is SILF.F's price volatile compared to industry and market?SILF.F volatilitySILF.F Average Weekly Movementn/aPharmaceuticals Industry Average Movement10.1%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%안정적인 주가: SILF.F의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.시간에 따른 변동성: Insufficient data to determine SILF.F의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트n/an/aMike Arnoldwww.silowellness.com더 보기Silo Wellness Inc. 기초 지표 요약Silo Wellness의 순이익과 매출은 시가총액과 어떻게 비교됩니까?SILF.F 기초 통계시가총액US$1.13m순이익 (TTM)US$511.02k매출 (TTM)US$275.89k2.2x주가수익비율(P/E)4.1x주가매출비율(P/S)SILF.F는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표SILF.F 손익계산서 (TTM)매출US$275.89k매출원가US$180.23k총이익US$95.66k기타 비용-US$415.36k순이익US$511.02k최근 보고된 실적Jul 31, 2023다음 실적 발표일해당 없음주당순이익(EPS)0.0033총이익률34.67%순이익률185.23%부채/자본 비율-47.5%SILF.F의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/11/25 18:14종가2023/08/28 00:00수익2023/07/31연간 수익2022/10/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Silo Wellness Inc.는 0명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Aug 30+ 1 more updateSilo Wellness Inc. announced that it expects to receive CAD 0.25 million in fundingSilo Wellness Inc. announced a best-efforts private placement to issue 12,500,000 common shares at a price of CAD 0.02 per share for the gross proceeds of CAD 250,000 on August 29, 2023.
공시 • Feb 18Silo Wellness Inc. Announces Resignation of Gerard Lee from as A Director of the BoardSilo Wellness Inc. accepted the resignation of Gerard Lee from his position as a director of the board, effective immediately. The board of directors includes Greg Biniowsky (independent director), Vancouver lawyer; Simon Bababeygy, M.D. (independent director), California physician; Michael Hartman, California pharmaceutical chemist; and Mike Arnold, Oregon lawyer.
공시 • Oct 18Silo Wellness Inc. (CNSX:SILO) completed the acquisition of Dyscovry Science Ltd.Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd. on May 31, 2022. Silo Wellness Inc. (CNSX:SILO) entered into a definitive share exchange agreement to acquire Dyscovry Science Ltd. on September 27, 2022. Pursuant to the terms of the Share Exchange Agreement, Silo will acquire 100% of the issued and outstanding shares of Dyscovry in exchange for 12,762,325 (for a total of 49% of the issued shares post closing of the transaction) common shares in the capital of Silo (the "Payment Shares"). The Payment Shares issued for shares of Dyscovry shall be subject to restrictions on resale for a period of 36 months from closing of the Acquisition and shall be released on a schedule consistent with the release schedule for an "emerging issuer" prescribed by section 4.3 of National Policy 46-201- Escrow for Initial Public Offerings. Silo has also agreed to pay approximately CAD 120,000 of Dyscovry founder's debt in twelve equal monthly installments, and in any event, the total debt shall be paid no later than twelve months from the Closing Date. Subject to the completion of the due diligence process and the completion of the definitive agreement, the transaction contemplates Silo will acquire 100% of the issued and outstanding shares of Dyscovry in exchange of 49% of the issued shares. Following closing, Dyscovry shall have the right to immediately nominate one director to the board of directors of Silo. Closing of the Transaction is subject to customary closing conditions and applicable regulatory approvals, including the approval of the CSE and the shareholders of Dyscovry if required. Silo Wellness Inc. (CNSX:SILO) completed the acquisition of Dyscovry Science Ltd. on October 17, 2022. Upon closing of the transaction, CFO Winfield Ding has resigned from the board of directors and Dyscovry founder Gerard Lee of Toronto has been appointed director. Winfield Ding will continue as Chief Financial Officer.
공시 • Jun 10Silo Wellness Inc. Announces Change of Chief Executive OfficerSilo Wellness Inc. announced that founder and chairman of the board of directors Mike Arnold is assuming the role of the company's interim chief executive officer to continue to lead the company through its planned acquisition of Dyscovry Science Ltd. and in its planned Oregon psilocybin business objectives. The company and former CEO Douglas K. Gordon have agreed to Mr. Gordon stepping down as CEO, but he will remain involved in the business, including pursuit of global distribution opportunities for sales of Marley One. During his tenure at Silo Wellness, Mr. Gordon was responsible for the creation of the Marley One global mushroom brand in collaboration with the family of legendary musician Bob Marley and for launching psychedelic retreats in Oregon and Jamaica, a first for a publicly traded company. He also led the Company through its public listing in March of 2021 and two major financings. CEO Mike Arnold founded Silo Wellness in 2018 and was CEO from inception until August 2020. He is an experienced Oregon trial attorney. As the company's president and chairman of the board of directors, he has been responsible for the Company's Ontario Securities Commission and Canadian Securities Exchange compliance, investor relations, financing, and corporate development. In the last five years he has successfully raised over $12 million for his startups. Mike received his Bachelor of Arts from Truman State University (Kirksville, Missouri) and Juris Doctor from the University of Oregon School of Law. He is an avid outdoorsman and rafting guide.
공시 • Jun 01Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd.Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd. on May 31, 2022. Subject to the completion of the due diligence process and the completion of the definitive agreement, the transaction contemplates Silo Wellness Inc. acquiring 100% of Dyscovry's shares in exchange for 49% of the issued outstanding securities of the Company.
공시 • Apr 15Silo Wellness Inc. announced that it expects to receive CAD 5.95 million in funding from Alpha Blue Ocean Investment GroupSilo Wellness Inc. announced that it has entered into an subscription agreement for a private placement of convertible debentures for gross proceeds of up to CAD 5,950,000 on April 14, 2022. The transaction will include participation from new investor Global Tech Opportunities 14, a fund managed by Alpha Blue Ocean Investment Group. The subscription agreement provides a commitment to fund the corporation up to CAD 5,950,000 by subscribing for CAD 7,300,000 aggregate principal amount of convertible debentures, inclusive of the commitment fee, in twenty tranches, each in the aggregate principal amount of CAD 350,000 each tranche convertible upon notice at the lower of the closing price of the common shares on the CSE at the time of delivery of the relevant conversion notice to the corporation and CAD 0.05; the convertible debentures shall be subscribed for at a subscription price of eighty-five percent of the par value of the convertible debentures. 41,650,000 warrants exercisable at CAD 0.05 shall be attached to the first tranche. In connection with the subscription agreement, the company has agreed to pay the subscriber a commitment fee of CAD 300,000 where CAD 150,000 shall be added to the principal amount of the debentures issued in connection with each of the first two tranches.
공시 • Aug 30+ 1 more updateSilo Wellness Inc. announced that it expects to receive CAD 0.25 million in fundingSilo Wellness Inc. announced a best-efforts private placement to issue 12,500,000 common shares at a price of CAD 0.02 per share for the gross proceeds of CAD 250,000 on August 29, 2023.
공시 • Feb 18Silo Wellness Inc. Announces Resignation of Gerard Lee from as A Director of the BoardSilo Wellness Inc. accepted the resignation of Gerard Lee from his position as a director of the board, effective immediately. The board of directors includes Greg Biniowsky (independent director), Vancouver lawyer; Simon Bababeygy, M.D. (independent director), California physician; Michael Hartman, California pharmaceutical chemist; and Mike Arnold, Oregon lawyer.
공시 • Oct 18Silo Wellness Inc. (CNSX:SILO) completed the acquisition of Dyscovry Science Ltd.Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd. on May 31, 2022. Silo Wellness Inc. (CNSX:SILO) entered into a definitive share exchange agreement to acquire Dyscovry Science Ltd. on September 27, 2022. Pursuant to the terms of the Share Exchange Agreement, Silo will acquire 100% of the issued and outstanding shares of Dyscovry in exchange for 12,762,325 (for a total of 49% of the issued shares post closing of the transaction) common shares in the capital of Silo (the "Payment Shares"). The Payment Shares issued for shares of Dyscovry shall be subject to restrictions on resale for a period of 36 months from closing of the Acquisition and shall be released on a schedule consistent with the release schedule for an "emerging issuer" prescribed by section 4.3 of National Policy 46-201- Escrow for Initial Public Offerings. Silo has also agreed to pay approximately CAD 120,000 of Dyscovry founder's debt in twelve equal monthly installments, and in any event, the total debt shall be paid no later than twelve months from the Closing Date. Subject to the completion of the due diligence process and the completion of the definitive agreement, the transaction contemplates Silo will acquire 100% of the issued and outstanding shares of Dyscovry in exchange of 49% of the issued shares. Following closing, Dyscovry shall have the right to immediately nominate one director to the board of directors of Silo. Closing of the Transaction is subject to customary closing conditions and applicable regulatory approvals, including the approval of the CSE and the shareholders of Dyscovry if required. Silo Wellness Inc. (CNSX:SILO) completed the acquisition of Dyscovry Science Ltd. on October 17, 2022. Upon closing of the transaction, CFO Winfield Ding has resigned from the board of directors and Dyscovry founder Gerard Lee of Toronto has been appointed director. Winfield Ding will continue as Chief Financial Officer.
공시 • Jun 10Silo Wellness Inc. Announces Change of Chief Executive OfficerSilo Wellness Inc. announced that founder and chairman of the board of directors Mike Arnold is assuming the role of the company's interim chief executive officer to continue to lead the company through its planned acquisition of Dyscovry Science Ltd. and in its planned Oregon psilocybin business objectives. The company and former CEO Douglas K. Gordon have agreed to Mr. Gordon stepping down as CEO, but he will remain involved in the business, including pursuit of global distribution opportunities for sales of Marley One. During his tenure at Silo Wellness, Mr. Gordon was responsible for the creation of the Marley One global mushroom brand in collaboration with the family of legendary musician Bob Marley and for launching psychedelic retreats in Oregon and Jamaica, a first for a publicly traded company. He also led the Company through its public listing in March of 2021 and two major financings. CEO Mike Arnold founded Silo Wellness in 2018 and was CEO from inception until August 2020. He is an experienced Oregon trial attorney. As the company's president and chairman of the board of directors, he has been responsible for the Company's Ontario Securities Commission and Canadian Securities Exchange compliance, investor relations, financing, and corporate development. In the last five years he has successfully raised over $12 million for his startups. Mike received his Bachelor of Arts from Truman State University (Kirksville, Missouri) and Juris Doctor from the University of Oregon School of Law. He is an avid outdoorsman and rafting guide.
공시 • Jun 01Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd.Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd. on May 31, 2022. Subject to the completion of the due diligence process and the completion of the definitive agreement, the transaction contemplates Silo Wellness Inc. acquiring 100% of Dyscovry's shares in exchange for 49% of the issued outstanding securities of the Company.
공시 • Apr 15Silo Wellness Inc. announced that it expects to receive CAD 5.95 million in funding from Alpha Blue Ocean Investment GroupSilo Wellness Inc. announced that it has entered into an subscription agreement for a private placement of convertible debentures for gross proceeds of up to CAD 5,950,000 on April 14, 2022. The transaction will include participation from new investor Global Tech Opportunities 14, a fund managed by Alpha Blue Ocean Investment Group. The subscription agreement provides a commitment to fund the corporation up to CAD 5,950,000 by subscribing for CAD 7,300,000 aggregate principal amount of convertible debentures, inclusive of the commitment fee, in twenty tranches, each in the aggregate principal amount of CAD 350,000 each tranche convertible upon notice at the lower of the closing price of the common shares on the CSE at the time of delivery of the relevant conversion notice to the corporation and CAD 0.05; the convertible debentures shall be subscribed for at a subscription price of eighty-five percent of the par value of the convertible debentures. 41,650,000 warrants exercisable at CAD 0.05 shall be attached to the first tranche. In connection with the subscription agreement, the company has agreed to pay the subscriber a commitment fee of CAD 300,000 where CAD 150,000 shall be added to the principal amount of the debentures issued in connection with each of the first two tranches.
공시 • Feb 04Silo Wellness Inc. announced that it expects to receive $0.494988 million in funding from Orthogonal Thinker, Inc., Investment ArmSilo Wellness Inc. announced that it has entered into an subscription agreement to issue 12,555,180 units at a price of $0.039425 per unit for gross proceeds of up to $494,988 on February 3, 2022. The transaction will include participation from new investor Orthogonal Thinker, Inc., Investment Arm. Each unit will consist of one common share and one common share purchase warrant. Each warrant will be exercisable at CAD 0.05 per share for two years following the closing date of the offering. The offering is subject to customary closing conditions, applicable regulatory approvals, including receipt of certain voting support agreements from certain shareholders of the company. David Nikzad and Jason Hobson from Orthogonal Thinker, Inc., Investment Arm will join company's board of director.
공시 • Jun 25Silo Wellness Inc. Debuts Marley One, the First Global Functional and Psychedelic Mushroom Brand, in Collaboration with the Bob Marley FamilySilo Wellness Inc. announced the launch of Marley One, the first global functional and psychedelic mushroom consumer brand, in collaboration with the family of Bob Marley. The initial product offering will include a range of functional mushroom tinctures with unique blends highlighting the brand’s connection to Jamaica, including species such as cordyceps, lion's mane, chaga, reishi and turkey tail that offer a range of unique health and wellness benefits, from immunity and gut health to cognitive function and sleep enhancement. The Company intends to launch a psychedelic mushroom product line under the Marley name later this year, to be followed by additional functional mushroom products including gummies, capsules and cosmetics. In March, Silo Wellness announced a multi-year licensing agreement with the family of global reggae icon Bob Marley for the exclusive worldwide rights to brand, market and sell a distinct product line of functional and psychedelic mushrooms. At launch, the Marley One product line includes: One Mind: A coffee-flavored blend of lion’s mane and L-theanine designed to improve focus and cognitive function. One Flow: A peppermint-flavored blend of cordyceps and ginseng designed to enhance physical endurance and mental function. One Harmony: A mango-flavored blend of chaga and ginger designed to stimulate gut health and improve digestion. One Body: A berry-flavored blend of turkey tail and astragalus designed to support immune health. One Rest: A vanilla-flavored blend of reishi and GABA designed to help reduce tension and stress and improve quality of sleep.
